Shares of Achillion Pharmaceuticals, Inc. ACHN were volatile in pre-market trading Monday, spiking up over 10 percent before falling more than 2 percent.
The movement in the stock followed the company’s announcement Monday of “positive results from two studies supporting a short duration, potentially best-in-disease regimen of its proprietary NS5A and nucleotide inhibitors, ACH-3102 and ACH-3422.”
"We believe that achievement of 100 percent SVR4 in six weeks in the ACH-3102 proxy study, combined with the high potency and safety demonstrated by ACH-3422, highlights the ability of our exceptional, fully owned portfolio to excel in the HCV market," commented Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion. "We look forward to initiating in 2015 short duration, pan-genotypic Phase 2 therapeutic trials to evaluate the doublet of ACH-3102 and ACH-3422, with the ultimate goal of improving patient care and access to treatment."
Achillion Pharmaceuticals, Inc recently traded unchanged in the pre-market at $16.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
